Remove 2002 Remove Clinical Trials Remove Conditions Remove Consumption
article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

In time, Western civilization caught on, and consumption expanded around the globe. Responsible consumption is key, and in the case of psychedelics – where you could potentially become detached from reality – it’s important to be in a safe space, preferably around people you’re comfortable with.

History 119
article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. We also used manifest textual analysis to search for word frequencies, and specific conditions referred to in the articles retrieved. Spasticity from neurological conditions. Background. Conclusions. Bonini et al.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. 2002 Jun;42(8):993-1007.